NovaBridge Biosciences Conference Call Summary Company Overview - **Company Name**: NovaBridge Biosciences (formerly I-Mab) - **Industry**: Biotechnology - **Focus**: Transitioned from an asset-based biotech company to a platform company aimed at bringing Chinese innovations to global markets [2][3] Key Points Business Transformation and Strategy - **Name Change**: The company rebranded from I-Mab to NovaBridge to reflect its new strategy [2] - **Strategic Pivot**: Shifted focus to leverage the Chinese biotech ecosystem for global innovation, recognizing the increase in in-licensing deals from 10% to 40% over three years [3] - **Competitive Advantage**: NovaBridge combines strong access to the Chinese biotech ecosystem with established operations in the U.S., differentiating it from many competitors [5][6] Givastomig Development - **Clinical Data**: Givastomig shows promising results in combination with Nivolumab and chemotherapy for gastroesophageal adenocarcinoma, with a progression-free survival (PFS) of approximately 17 months, significantly better than existing treatments [11][15] - **Efficacy Consistency**: The data shows consistent objective response rates of 70%-80% across various patient subgroups [15][16] - **Comparison with Competitors**: Givastomig's PFS is superior to other treatments like CheckMate 649 (7.7 months) and SPOTLIGHT (10.5 months) [15][16] - **Safety Profile**: The treatment has a manageable toxicity profile, with gastritis being the only notable side effect [11][19] Future Development Plans - **Clinical Trials**: Plans to conduct randomized trials to validate the efficacy of Givastomig, addressing concerns about single-arm study limitations [15][30] - **Patient Stratification**: Future studies will focus on patients with claudin 18.2 expression levels of 1% or greater, ensuring a representative patient population [26][29] VIS-101 Update - **Clinical Data**: VIS-101 demonstrated favorable safety and efficacy, with two-thirds of patients remaining treatment-free for four months and half for six months, outperforming Vabysmo [42][43] - **Mechanism of Action**: The molecule targets VEGF-A and Ang2, showing a twofold improvement in VEGF-A and a 17-fold improvement in Angiopoietin-2 binding affinity compared to competitors [50][51] IPO Plans - **Hong Kong IPO**: The company is adjusting its IPO plans due to regulatory requirements, aiming for a valuation that reflects its pipeline's inherent value before proceeding [60] Market Competition - **Competitive Landscape**: The gastric cancer treatment market is becoming increasingly competitive, with multiple companies developing similar therapies. NovaBridge aims to position Givastomig as a best-in-class option [30][34] Additional Insights - **Regulatory Engagement**: Positive interactions with the FDA regarding Givastomig's development strategy indicate strong regulatory support [34] - **Future Innovations**: The company is exploring novel bispecific and tri-specific agents to enhance its therapeutic offerings [38] Conclusion NovaBridge Biosciences is strategically positioned to leverage its unique access to the Chinese biotech ecosystem while developing promising therapies like Givastomig and VIS-101. The company is focused on rigorous clinical validation and regulatory engagement to ensure successful market entry and competitive positioning in the biotechnology landscape.